Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 63 clinical trials
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer

in this study are: Dabrafenib Trametinib PDR001

measurable disease
BRAF
KRAS
neutrophil count
ct scan
  • 1 views
  • 22 Jan, 2021
Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

This phase II trial studies the side effects and how well dabrafenib and trametinib work in treating patients with Erdheim Chester disease that have BRAF V600 gene mutations. Dabrafenib and

  • 7 views
  • 23 Jul, 2020
  • 1 location
A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC

The purpose of this study is to evaluate the safety and efficacy of dabrafenib in combination with trametinib in Chinese patients with BRAF V600E mutation-positive metastatic Non-Small Cell Lung

metastasis
secondary malignant neoplasm of liver
measurable disease
BRAF
stage iv non-small cell lung cancer
  • 0 views
  • 25 Jan, 2021
  • 6 locations
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer

This is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV600E mutation.

  • 3 views
  • 23 Jan, 2021
MEK and Autophagy Inhibition in Metastatic/Locally Advanced Unresectable Neuroblastoma RAS (NRAS) Melanoma

pancreatic adenocarcinoma. The study team has shown in vivo, in four different NRAS mutated melanoma Patient Derived Xenograft (PDX) models that the combination of the MEK inhibitor trametinib and the

  • 0 views
  • 25 Jan, 2021
  • 5 locations
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

>Pembrolizumab (Keytruda) Trametinib (Mekinist) Dabrafenib (Tafinlar)

  • 8 views
  • 08 Dec, 2019
Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy

dabrafenib + trametinib with ipilimumab failed due to toxicity. Patients with elevated levels of serum LDH are less likely to respond to immunotherapy compared to patients with normal LDH levels

  • 5 views
  • 24 Jan, 2021
  • 13 locations
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

This is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.

  • 0 views
  • 25 Jan, 2021
  • 1 location
Encorafenib Plus Binimetinib for People With BRAF V600E Mutated Relapsed/Refractory HCL

Background Hairy cell leukemia (HCL) does not usually respond to chemotherapy. Most people with HCL have a BRAF gene mutation. This can increase the growth of cancer cells. Vemurafenib has been tested to treat these people. However, researchers think a combination of drugs might work better. Objective To test if …

  • 0 views
  • 17 Jan, 2021
  • 1 location
Dabrafenib and/or Trametinib Rollover Study

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former

dabrafenib
trametinib
  • 87 views
  • 03 Jan, 2021
  • 12 locations